Conditions: Metastatic Colorectal Cancer
Keywords: Best Supportive Care Panitumumab Chemorefractory Wild-type KRAS Overall Survival Phase 3
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 377
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the benefit of panitumumab in addition to best supportive care compared to best supportive care alone in patients with chemorefractory wild-type KRAS (Kirsten rat sarcoma viral oncogene homolog) metastatic colorectal cancer.

Detailed description:

Arms:
arm 1: Participants received panitumumab administered intravenously 6 mg/kg every 14 days plus BSC until disease progression, withdrawal of consent, death, or intolerance of study drug. arm 2: Participants received best supportive care until disease progression, withdrawal of consent, or death.

Interventions: intervention 1: Best Supportive Care (BSC) intervention 2: Panitumumab
Intervention descriptions: intervention 1: BSC was defined as the best palliative care available as judged appropriate by the investigator and according to institutional guidelines and could include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy as clinically indicated. intervention 2: Administered intravenously

Protocol document: